Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accumulated Expenses (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Accumulated Expenses for 16 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 26.8% to $8.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Dec 2025, up 26.8% year-over-year, with the annual reading at $8.7 million for FY2025, 26.8% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $8.7 million at Anika Therapeutics, down from $14.4 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $19.8 million in Q3 2023, with the low at $6.0 million in Q2 2025.
  • Average Accumulated Expenses over 5 years is $12.8 million, with a median of $13.0 million recorded in 2021.
  • Peak annual rise in Accumulated Expenses hit 410.46% in 2021, while the deepest fall reached 63.87% in 2021.
  • Over 5 years, Accumulated Expenses stood at $17.8 million in 2021, then plummeted by 36.67% to $11.3 million in 2022, then increased by 24.44% to $14.1 million in 2023, then plummeted by 51.46% to $6.8 million in 2024, then increased by 26.8% to $8.7 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $8.7 million, $14.4 million, and $6.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.